Literature DB >> 35903658

Surgical Management of Rhabdomyosarcoma of the Nasal Cavity and Paranasal Sinuses: Analysis of Operative Indications, Settings, and Outcomes.

Lulia A Kana1, Joshua D Smith1, Emily L Bellile2, Rashmi Chugh3, Erin L McKean1,4.   

Abstract

Objectives  The role of surgery in management of sinonasal rhabdomyosarcoma (SNRMS) has traditionally been limited, owing to anatomic and technological challenges and the established role of systemic therapy. Herein, we report our institutional experience with surgical management of SNRMS, with a particular focus on operative approaches, extent and outcomes. Design  This study is a retrospective cohort study. Setting  This study was conducted at a single-institution, academic center. Participants  Patients of any age with histologically confirmed RMS of the nasal cavity, maxillary, ethmoid, frontal, or sphenoid sinus, nasolacrimal duct, or nasopharynx presenting between 1994 and 2020 were included in this study. Main Outcome Measures  Demographics, tumor characteristics, operative settings, complications and recurrence, and survival outcomes were the primary outcomes of this study. Results  Our study cohort comprised of 29 patients (mean [range] age: 27.0 [3.1-65.7], n  = 12 [41%] female). Tumors of the nasal cavity ( n  = 10, 35%) and ethmoid sinuses ( n  = 10, 35%) and those with alveolar histology ( n  = 21, 72%) predominated. Patients who had surgery as part of their treatment ( n  = 13, 45%) had improved distant metastasis-free survival (DMFS) overall (hazard ratio [HR]: 0.32, 95% CI: 0.11, 0.98, p  = 0 .05 ) as compared with those who did not have surgery. Surgical approaches included open ( n  = 7), endoscopic ( n  = 4), and combined ( n  = 2). Eight of these 13 patients (62%) had an R0 resection. Additionally, surgical salvage of recurrent disease was employed in five patients (17%). Conclusion  SNRMS is an aggressive malignancy with a high rate of recurrence and spread requiring a multidisciplinary approach for optimal outcomes. Our data supports an expanding role for surgery for SNRMS given its feasibility, tolerability, and potential to improve outcomes. Thieme. All rights reserved.

Entities:  

Keywords:  endoscopic; image guidance; nasal cavity; parameningeal; paranasal sinus; rhabdomyosarcoma; surgery

Year:  2021        PMID: 35903658      PMCID: PMC9324297          DOI: 10.1055/s-0041-1736590

Source DB:  PubMed          Journal:  J Neurol Surg B Skull Base        ISSN: 2193-634X


  24 in total

1.  Local control of parameningeal rhabdomyosarcoma: outcomes in non-complete responders to chemoradiation.

Authors:  Arnold C Paulino; Nancy Bauman; James H Simon; Thanh X Nguyen; Justine M Ritchie; Raymond Tannous
Journal:  Med Pediatr Oncol       Date:  2003-08

2.  Clinicopathologic traits and prognostic factors associated with pediatric sinonasal rhabdomyosarcoma.

Authors:  Sana H Siddiqui; Emaad Siddiqui; Rich D Bavier; Nirali M Patel; Suat Kiliç; Soly Baredes; Wayne D Hsueh; Jean Anderson Eloy
Journal:  Int Forum Allergy Rhinol       Date:  2019-01-10       Impact factor: 3.858

Review 3.  Pediatric rhabdomyosarcoma of the head and neck.

Authors:  M Boyd Gillespie; David T Marshall; Terry A Day; Allen O Mitchell; David R White; Julio C Barredo
Journal:  Curr Treat Options Oncol       Date:  2006-01

Review 4.  The role of surgery in children with head and neck rhabdomyosarcoma and Ewing's sarcoma.

Authors:  P Gradoni; D Giordano; G Oretti; M Fantoni; T Ferri
Journal:  Surg Oncol       Date:  2010-02-24       Impact factor: 3.279

Review 5.  Update on rhabdomyosarcoma.

Authors:  Roshni Dasgupta; David A Rodeberg
Journal:  Semin Pediatr Surg       Date:  2012-02       Impact factor: 2.754

Review 6.  Treatment for childhood rhabdomyosarcoma: the cost of cure.

Authors:  Michael C G Stevens
Journal:  Lancet Oncol       Date:  2005-02       Impact factor: 41.316

7.  Delayed primary excision with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.

Authors:  David A Rodeberg; Moody D Wharam; Elizabeth R Lyden; Julie A Stoner; Kenneth Brown; Suzanne L Wolden; Charles N Paidas; Sarah S Donaldson; Douglas S Hawkins; Sheri L Spunt; Carola A Arndt
Journal:  Int J Cancer       Date:  2014-12-10       Impact factor: 7.396

8.  Prognostic significance of staging factors of the UICC staging system in childhood rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS-II).

Authors:  W Lawrence; E A Gehan; D M Hays; M Beltangady; H M Maurer
Journal:  J Clin Oncol       Date:  1987-01       Impact factor: 44.544

9.  The Intergroup Rhabdomyosarcoma Study-I. A final report.

Authors:  H M Maurer; M Beltangady; E A Gehan; W Crist; D Hammond; D M Hays; R Heyn; W Lawrence; W Newton; J Ortega
Journal:  Cancer       Date:  1988-01-15       Impact factor: 6.860

10.  Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV.

Authors:  John C Breneman; Elizabeth Lyden; Alberto S Pappo; Michael P Link; James R Anderson; David M Parham; Stephen J Qualman; Moody D Wharam; Sarah S Donaldson; Harold M Maurer; William H Meyer; K Scott Baker; Charles N Paidas; William M Crist
Journal:  J Clin Oncol       Date:  2003-01-01       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.